bf/NASDAQ:RXDX_icon.jpeg

NASDAQ:RXDX

Prometheus Biosciences, Inc.

  • Stock

USD

Last Close

199.74

15/06 20:00

Market Cap

9.56B

Beta: −0.60

Volume Today

1.79M

Avg: 983.04K

PE Ratio

−63.62

PFCF: −88.63

Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative ...Show More

Earnings

Earnings per Share (Estimate*)

-1.5-1-0.52014-03-312015-09-302017-03-312021-03-122022-08-11

Revenue (Estimate*)

1M2M3M4M2014-03-312015-09-302017-03-312021-03-122022-08-11

*Estimate based on analyst consensus